tranilast

Known as: 2-((3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid, 2-{[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino}benzoic acid, N-(3',4'-dimethoxycinnamoyl)anthranilic acid 
 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (6)

Anti-Allergic AgentsAnti-Inflammatory Agents, Non-SteroidalCalcium Channel BlockersHistamine H1 Antagonists
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Tranilast inhibits the growth and metastasis of mammary carcinoma.
Tranilast (N-[3,4-dimethoxycinnamonyl]-anthranilic acid) is a drug of low toxicity that is orally administered, and has been used… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2007
Review
2007
Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations
Transforming growth factor β (TGF-β) is a highly pleiotropic cytokine that plays an important role in wound healing, angiogenesis… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
2006
2006
Effect of tranilast in early-stage diabetic nephropathy.
BACKGROUND Tranilast is an antifibrotic drug known to suppress collagen synthesis by fibroblasts by interfering with the effects… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta.
OBJECTIVE The pathological accumulation of extracellular matrix is a characteristic feature of diabetic cardiomyopathy that is… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats.
OBJECTIVE In order to study the association between myocardial fibrosis and inflammatory cell infiltration in the hypertensive… (More)
Is this relevant?
2003
2003
Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.
BACKGROUND/AIMS Tubulointerstitial pathology with the accumulation of extracellular matrix are pathological hallmarks of diabetic… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.
BACKGROUND Restenosis after percutaneous coronary intervention (PCI) is a major problem affecting 15% to 30% of patients after… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2002
2002
Effects of tranilast on filtering blebs: a pilot study.
PURPOSE To investigate the effects of topical instillation of 0.5% tranilast eye drops on intraocular pressure (IOP) and bleb… (More)
Is this relevant?
1999
1999
Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT).
BACKGROUND Tranilast is an antiallergic drug that suppresses the release of cytokines such as platelet-derived growth factor… (More)
Is this relevant?
Highly Cited
1992
Highly Cited
1992
The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts.
Tranilast, an anti-allergic drug inhibiting the release of substances such as histamine and prostaglandins from mast cells, was… (More)
Is this relevant?